Therapeutic or Preventive Procedure – Page 6

Eli Lilly to Acquire Adverum Biotechnologies in Gene Therapy Deal; Captain T Cell Secures €20M Funding

4 weeks ago talkbio0Tagged Acquisition, Adverum Biotechnologies, biotech, Captain T Cell, contingent value rights, CVR, eli lilly, financing characteristics, gene therapy, Investments, Ixo-vec, Ophthalmology specialty

Eli Lilly; Adverum Biotechnologies; Acquisition; Gene therapy; Ixo-vec; Contingent Value Rights (CVR); Ophthalmology; Captain T Cell; Financing; Biotech investment

Artios Pharma Raises $115 Million Series D to Advance DNA Damage Response Cancer Therapies

4 weeks ago talkbio0Tagged alnodesertib, ART6043, Artios Pharma, Cancer Therapeutic Procedure, cellular response to DNA damage stimulus, Clinical Trials, Colorectal Carcinoma, DDR, investors, Malignant neoplasm of breast, Oncology Pipeline, Pancreatic carcinoma, Series D financing

Artios Pharma; Series D financing; DNA Damage Response (DDR); cancer therapies; alnodesertib; ART6043; oncology pipeline; pancreatic cancer; colorectal cancer; breast cancer; investors; clinical trials

NewcelX Appoints Jeremy Shefner to Scientific Advisory Board

4 weeks ago talkbio0Tagged ALS, Amyotrophic Lateral Sclerosis, AstroRx ®, Barrow Neurological Institute, Cell Therapy, Clinical Trials, Jeremy Shefner, Neurodegenerative Disorders, NewcelX, Scientific Advisory Board

NewcelX; Jeremy Shefner; Scientific Advisory Board; ALS; AstroRx; neurodegenerative disease; Barrow Neurological Institute; cell therapy; clinical trials

FDA Imposes Boxed Warning and Restricts Use of Sarepta’s Elevidys Gene Therapy for Duchenne Muscular Dystrophy

4 weeks ago talkbio0Tagged Black Box Warning, ELEVIDYS, gene therapy, Indication restriction, Liver Failure, Acute, Muscular Dystrophy, Duchenne, Post-marketing study, Safety labeling, United States Food and Drug Administration

Elevidys; Sarepta Therapeutics; Duchenne muscular dystrophy; FDA; Boxed warning; Gene therapy; Acute liver failure; Safety labeling; Indication restriction; Post-marketing study

Pfizer Reduces Stake in BioNTech; Candel Pauses Pancreatic Cancer Program

4 weeks ago talkbio0Tagged Acquisition, BioNTech, Comirnaty, expansion, Metsera, mRNA Vaccine, Pancreatic carcinoma, Pfizer, pipeline

Pfizer; BioNTech; stake reduction; Candel Therapeutics; pancreatic cancer; Comirnaty; mRNA vaccine; Metsera acquisition; pipeline expansion

Gate Bioscience Captures $65M Series B to Advance Molecular Gate Protein Degradation Platform

1 month ago talkbio0Tagged Bio + Health, eli lilly, Forbion, Gate Bioscience, innovation, Molecular Gates, Precision Medicine, Protein Degradation, Metabolic, protein elimination therapeutics, Series B funding

Gate Bioscience; protein degradation; protein elimination therapeutics; Series B funding; Molecular Gates; Eli Lilly; Forbion; a16z Bio + Health; precision medicine; biotech innovation

FDA Moves to Remove Black Box Warnings from Menopausal Hormone Therapies

1 month ago talkbio0Tagged Black Box Warning, estrogens, Hormone replacement therapy, Hormone Therapy, labeling change, Menopausal symptom, Menopause, Progestins, United States Food and Drug Administration, women 's health

FDA; menopause; hormone therapy; black box warning; HRT; estrogen; progestogen; labeling change; women’s health; menopausal symptoms

Voyager Therapeutics Partners with Transition Bio for Small Molecule Neurodegenerative Drug Discovery; CRISPR Therapeutics Ends Work on CAR-T Therapy

1 month ago talkbio0Tagged Amyotrophic Lateral Sclerosis, CAR-T therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Development, Neurodegenerative Disorders, Partnership, Pick Disease of the Brain, small molecule drug discovery, TARDBP gene, Transition Bio, Voyager Therapeutics

Voyager Therapeutics; Transition Bio; ALS; frontotemporal dementia; TDP-43; small molecule drug discovery; neurodegenerative diseases; CRISPR Therapeutics; CAR-T therapy; partnership; drug development

From Weight Loss to Hair Loss: The Search for the Next Blockbuster – Recent Developments and News (2024-2025)

1 month ago talkbio0Tagged Alopecia, Androgenetic Alopecia, baldness cure, blockbuster drugs, Glucagon-Like Peptide 1, Investments, minoxidil, pattern hair loss, Pelage Pharmaceuticals, PP405, Veradermics, Weight-Loss Agents

weight loss drugs; GLP-1; hair loss treatments; Pelage Pharmaceuticals; Veradermics; blockbuster drugs; pattern hair loss; baldness cure; minoxidil; PP405; androgenetic alopecia; biotech investment

Spotlight On: What to Watch at AHA 2025 – Key Science and Trends

1 month ago talkbio0Tagged 2025, Autoimmune hemolytic anemia, Cardiology discipline, cardiometabolic, Cardiopulmonary Resuscitation, Clinical Trials, coronary trials, gene editing therapies, Guidelines, Hypertensive disease, Interventional procedure, lipid management, Medical Valves, polypill, Science

AHA 2025; late-breaking science; clinical trials; cardiology; gene-editing therapies; polypill; lipid management; valve and coronary trials; cardiometabolic intervention; hypertension; CPR guidelines